Abstract
Carvedilol has been shown to improve survival and morbidity in patients with heart failure. It has been demonstrated that carvedilol use is associated with dose-dependent reduction in QT dispersion (QTd) independent of the cause of heart failure, suggesting that reduction in QTd may be a mechanism by which carvedilol improves outcomes in heart failure.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Adrenergic alpha-Antagonists / administration & dosage*
-
Adrenergic alpha-Antagonists / pharmacology*
-
Adult
-
Aged
-
Carbazoles / administration & dosage*
-
Carbazoles / pharmacology*
-
Carvedilol
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Electrocardiography
-
Female
-
Heart Failure / drug therapy*
-
Heart Rate / drug effects*
-
Humans
-
Male
-
Middle Aged
-
Placebos
-
Propanolamines / administration & dosage*
-
Propanolamines / pharmacology*
Substances
-
Adrenergic alpha-Antagonists
-
Carbazoles
-
Placebos
-
Propanolamines
-
Carvedilol